Hi-Clearance (1788) reported revenue of NT$378.8 million for Oct 2026, +1.4% year on year and -8.7% from the previous month. Revenue for Jan–Oct 2026 was NT$3.79 billion (+6.5% year on year).
Year-on-year revenue growth: 17 months in a row. →
In Oct 2026, it ranked No. 23 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$378.8 million | +1.4% | -8.7% |
| Sep 2026 | NT$414.8 million | +14.9% | +8.3% |
| Aug 2026 | NT$383.2 million | +8.9% | +5.6% |
| Jul 2026 | NT$362.9 million | +2.8% | -7.6% |
| Jun 2026 | NT$392.8 million | +3.7% | +13.8% |
| May 2026 | NT$345.2 million | +4.3% | -6.6% |
| Apr 2026 | NT$369.6 million | +2.6% | -5.7% |
| Mar 2026 | NT$392 million | +6.0% | +18.0% |
| Feb 2026 | NT$332.3 million | +6.9% | -21.1% |
| Jan 2026 | NT$420.9 million | +13.8% | +7.3% |
| Dec 2025 | NT$392.3 million | +7.9% | +20.2% |
| Nov 2025 | NT$326.3 million | +8.1% | -12.6% |
| Oct 2025 | NT$373.4 million | +11.0% | +3.5% |
| Sep 2025 | NT$361 million | +6.7% | +2.6% |
| Aug 2025 | NT$351.7 million | +2.1% | -0.4% |
| Jul 2025 | NT$353 million | +8.2% | -6.8% |
| Jun 2025 | NT$378.8 million | +7.5% | +14.5% |
| May 2025 | NT$330.9 million | -1.2% | -8.2% |
| Apr 2025 | NT$360.4 million | -12.1% | -2.5% |
| Mar 2025 | NT$369.8 million | +16.1% | +18.9% |
| Feb 2025 | NT$310.9 million | +11.2% | -15.9% |
| Jan 2025 | NT$369.9 million | +0.8% | +1.7% |
| Dec 2024 | NT$363.7 million | +4.1% | +20.5% |
| Nov 2024 | NT$301.7 million | -5.1% | -10.3% |
| Oct 2024 | NT$336.5 million | +6.9% | -0.5% |
Jan–Oct 2026 cumulative: NT$3.79 billion (+6.5% YoY)
Other Biotech & Medical companies
Compare with peers: Hi-Clearance vs PEC / Hi-Clearance vs Lotus Pharm / Hi-Clearance vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16